Ribavirin - Roche
Alternative Names: Copegus; Pegasys RBV; R964Latest Information Update: 05 Nov 2023
At a glance
- Originator Roche
- Developer Chugai Pharmaceutical; Roche
- Class Antivirals; Furans; Ribonucleosides; Small molecules; Triazoles
- Mechanism of Action Nucleic acid inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Hepatitis C
Most Recent Events
- 13 Feb 2019 Chemical structure information added
- 26 Mar 2015 The Japanese MHLW approves ribavirin (Copegus®) in combination with sofosbuvir for use in genotype 2 Hepatitis C patients with compensated cirrhosis related to Hepatitis C (Combination therapy) in Japan
- 04 Feb 2013 Launched for Hepatitis C (Combination therapy) in Canada (PO)